Alnylam Strengthens Cardiovascular Portfolio with New Vutrisiran and Zilebesiran Data
Event summary
- Alnylam presented new data at ACC.26 supporting vutrisiran as a first-line treatment for ATTR-CM, showing sustained benefits across disease severity.
- HELIOS-B analyses demonstrated vutrisiran reduced the risk of progression to advanced disease and improved survival in ATTR-CM patients.
- Zilebesiran showed promising safety data in Phase 2 trials, reinforcing its potential for hypertension management with biannual dosing.
- Real-world data indicated high adherence to vutrisiran treatment, with 93.8% of patients adherent after 12 months.
The big picture
Alnylam's latest data reinforces the potential of RNAi therapeutics in cardiovascular disease, positioning vutrisiran as a key player in ATTR-CM treatment and zilebesiran as a promising candidate for hypertension management. The findings come at a time when cardiovascular disease remains a leading global health crisis, driving demand for innovative and effective treatments. Alnylam's ability to deliver durable clinical benefits could significantly impact the cardiovascular therapeutic landscape.
What we're watching
- Therapeutic Efficacy
- How vutrisiran's demonstrated benefits in advanced ATTR-CM patients will impact its adoption as a first-line treatment.
- Regulatory Pathway
- Whether zilebesiran's Phase 3 ZENITH trial will confirm its potential for hypertension management and cardiovascular risk reduction.
- Market Positioning
- The pace at which Alnylam can scale its cardiovascular portfolio to compete with established hypertension treatments.